ATE255894T1 - Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen - Google Patents
Mglur5 antagonisten zur behandlung von schmerzen und angstzuständenInfo
- Publication number
- ATE255894T1 ATE255894T1 AT99948905T AT99948905T ATE255894T1 AT E255894 T1 ATE255894 T1 AT E255894T1 AT 99948905 T AT99948905 T AT 99948905T AT 99948905 T AT99948905 T AT 99948905T AT E255894 T1 ATE255894 T1 AT E255894T1
- Authority
- AT
- Austria
- Prior art keywords
- pain
- treatment
- anxiety
- antagonists
- mglur5 antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 229940124807 mGLUR antagonist Drugs 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9821503.1A GB9821503D0 (en) | 1998-10-02 | 1998-10-02 | Organic compounds |
| US22081398A | 1998-12-23 | 1998-12-23 | |
| PCT/EP1999/007239 WO2000020001A1 (en) | 1998-10-02 | 1999-09-30 | Mglur5 antagonists for the treatment of pain and anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE255894T1 true ATE255894T1 (de) | 2003-12-15 |
Family
ID=26314451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99948905T ATE255894T1 (de) | 1998-10-02 | 1999-09-30 | Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1117403B1 (https=) |
| JP (1) | JP2002526408A (https=) |
| KR (1) | KR20010088832A (https=) |
| CN (1) | CN1187048C (https=) |
| AT (1) | ATE255894T1 (https=) |
| AU (1) | AU765644B2 (https=) |
| BR (1) | BR9914215A (https=) |
| CA (1) | CA2345137A1 (https=) |
| DE (1) | DE69913548T2 (https=) |
| DK (1) | DK1117403T3 (https=) |
| ES (1) | ES2213389T3 (https=) |
| HU (1) | HUP0200553A3 (https=) |
| ID (1) | ID29095A (https=) |
| IL (2) | IL142047A0 (https=) |
| NO (1) | NO20011440L (https=) |
| NZ (1) | NZ510743A (https=) |
| PL (1) | PL202906B1 (https=) |
| PT (1) | PT1117403E (https=) |
| RU (1) | RU2232017C2 (https=) |
| SK (1) | SK4382001A3 (https=) |
| WO (1) | WO2000020001A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0005700D0 (en) * | 2000-03-09 | 2000-05-03 | Glaxo Group Ltd | Therapy |
| PT1345609E (pt) | 2000-12-22 | 2005-08-31 | Hoffmann La Roche | Derivados de tetra-hidro-(benzo ou tieno)-azepina-pirazina como antagonistas de mglur 1 |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| SE0303418D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 1 |
| SE0303419D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 11 |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| DE102005062985A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| ES2610508T3 (es) | 2006-11-22 | 2017-04-27 | Clinical Research Associates, Llc | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012054724A1 (en) | 2010-10-21 | 2012-04-26 | Massachusetts Institute Of Technology | Methods of treating seizure disorders |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| EP2557183A1 (de) | 2011-08-12 | 2013-02-13 | Siemens Aktiengesellschaft | Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts |
| JP2015525202A (ja) | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態 |
| LT3303316T (lt) | 2015-06-03 | 2020-05-11 | F. Hoffmann-La Roche Ag | Etinilo dariniai |
| CA3066711A1 (en) | 2017-07-31 | 2019-02-07 | Novartis Ag | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
| EP3459939A1 (en) | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Novel heterocyclic compounds as modulators of mglur7 |
| KR102027368B1 (ko) * | 2018-05-29 | 2019-10-01 | 서울대학교산학협력단 | 통증의 강도를 측정하는 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2056983T3 (es) * | 1988-03-21 | 1994-10-16 | Boehringer Ingelheim Pharma | Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa. |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
-
1999
- 1999-09-30 EP EP99948905A patent/EP1117403B1/en not_active Revoked
- 1999-09-30 CA CA002345137A patent/CA2345137A1/en not_active Abandoned
- 1999-09-30 ES ES99948905T patent/ES2213389T3/es not_active Expired - Lifetime
- 1999-09-30 HU HU0200553A patent/HUP0200553A3/hu unknown
- 1999-09-30 AU AU61984/99A patent/AU765644B2/en not_active Ceased
- 1999-09-30 SK SK438-2001A patent/SK4382001A3/sk unknown
- 1999-09-30 RU RU2001111868/14A patent/RU2232017C2/ru not_active IP Right Cessation
- 1999-09-30 PL PL346876A patent/PL202906B1/pl not_active IP Right Cessation
- 1999-09-30 ID IDW20010730A patent/ID29095A/id unknown
- 1999-09-30 KR KR1020017004152A patent/KR20010088832A/ko not_active Ceased
- 1999-09-30 BR BR9914215-5A patent/BR9914215A/pt not_active Application Discontinuation
- 1999-09-30 PT PT99948905T patent/PT1117403E/pt unknown
- 1999-09-30 WO PCT/EP1999/007239 patent/WO2000020001A1/en not_active Ceased
- 1999-09-30 DK DK99948905T patent/DK1117403T3/da active
- 1999-09-30 DE DE69913548T patent/DE69913548T2/de not_active Revoked
- 1999-09-30 CN CNB998117110A patent/CN1187048C/zh not_active Expired - Fee Related
- 1999-09-30 JP JP2000573360A patent/JP2002526408A/ja active Pending
- 1999-09-30 IL IL14204799A patent/IL142047A0/xx active IP Right Grant
- 1999-09-30 NZ NZ510743A patent/NZ510743A/en unknown
- 1999-09-30 AT AT99948905T patent/ATE255894T1/de active
-
2001
- 2001-03-15 IL IL142047A patent/IL142047A/en not_active IP Right Cessation
- 2001-03-21 NO NO20011440A patent/NO20011440L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9914215A (pt) | 2001-07-03 |
| CA2345137A1 (en) | 2000-04-13 |
| NZ510743A (en) | 2003-10-31 |
| ES2213389T3 (es) | 2004-08-16 |
| NO20011440D0 (no) | 2001-03-21 |
| KR20010088832A (ko) | 2001-09-28 |
| CN1187048C (zh) | 2005-02-02 |
| NO20011440L (no) | 2001-05-15 |
| EP1117403A1 (en) | 2001-07-25 |
| EP1117403B1 (en) | 2003-12-10 |
| IL142047A0 (en) | 2002-03-10 |
| DE69913548T2 (de) | 2004-09-23 |
| AU6198499A (en) | 2000-04-26 |
| HUP0200553A2 (hu) | 2002-07-29 |
| ID29095A (id) | 2001-07-26 |
| JP2002526408A (ja) | 2002-08-20 |
| CN1321087A (zh) | 2001-11-07 |
| PL346876A1 (en) | 2002-03-11 |
| SK4382001A3 (en) | 2001-08-06 |
| AU765644B2 (en) | 2003-09-25 |
| PT1117403E (pt) | 2004-04-30 |
| RU2232017C2 (ru) | 2004-07-10 |
| IL142047A (en) | 2007-09-20 |
| DE69913548D1 (de) | 2004-01-22 |
| HUP0200553A3 (en) | 2002-11-28 |
| WO2000020001A1 (en) | 2000-04-13 |
| PL202906B1 (pl) | 2009-08-31 |
| DK1117403T3 (da) | 2004-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE255894T1 (de) | Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen | |
| DE60223694D1 (de) | Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums | |
| DE60118544D1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
| DE60233040D1 (de) | Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese | |
| ATE422358T1 (de) | Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen | |
| ATE267595T1 (de) | Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten | |
| DE60023043D1 (de) | (S,S)-Reboxetin zur Behandlung von Inkontinenz | |
| DE60108080D1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| ATE323661T1 (de) | Behandlung von mineralischen stoffen | |
| DE69928542D1 (de) | 5ht2-agoniste zur behandlung des glaukoms | |
| DE60108857D1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
| DE60140516D1 (de) | Behandlung von fluorkohlenstoff- ausgangsmaterialien | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| DE60030861D1 (de) | Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen | |
| EP1117395A4 (en) | COMPOUNDS FOR THE TREATMENT OF ESTROGEN-RELATED DISEASES, METHODS OF PRODUCTION AND METHODS OF USE | |
| DE60016047D1 (de) | Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| ATE273276T1 (de) | Cyclobutendion-derivate zur behandlung von artherosclerose | |
| DE60233740D1 (de) | Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit | |
| DE60102812D1 (de) | Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose | |
| DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
| DE60036723D1 (de) | Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1117403 Country of ref document: EP |